H M Vargas
Overview
Explore the profile of H M Vargas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Friedrichs G, Abernathy M, Ackley D, Clark M, DaSilva J, Foley C, et al.
Regul Toxicol Pharmacol
. 2024 Sep;
153:105706.
PMID: 39293707
Optimization of ICH safety guideline studies for inclusion into regulatory submissions is critical for resource conservation, animal use reduction, and efficient drug development. The ICH S7A guidance for Safety Pharmacology...
2.
Pugsley M, Authier S, Koerner J, Redfern W, Markgraf C, Brabham T, et al.
J Pharmacol Toxicol Methods
. 2018 Nov;
95:1.
PMID: 30399523
No abstract available.
3.
Pugsley M, Authier S, Koerner J, Redfern W, Markgraf C, Brabham T, et al.
J Pharmacol Toxicol Methods
. 2018 Jan;
93:35-45.
PMID: 29330132
Safety Pharmacology studies are conducted to characterize the confidence by which biologically active new chemical entities (NCE) may be anticipated as safe. Non-clinical safety pharmacology studies aim to detect and...
4.
Derakhchan K, Chui R, Stevens D, Gu W, Vargas H
Br J Pharmacol
. 2013 Dec;
171(2):509-22.
PMID: 24372552
Background And Purpose: During repeat-dose toxicity studies, ECGs are collected from chemically or physically-restrained animals over a short timeframe. This is problematic due to cardiovascular changes caused by manual restraint...
5.
Brooks K, Cai J, Sandrasagra A, Roehr J, Errazo R, Vargas H
Proc West Pharmacol Soc
. 2000 Mar;
42:67-9.
PMID: 10697693
No abstract available.
6.
Hubbard J, Nordstrom S, Smith C, Brooks K, Zhou L, Vargas H
J Pharmacol Exp Ther
. 1997 Apr;
281(1):337-46.
PMID: 9103515
Besipirdine displays potent adrenergic activity in a variety of pharmacological and behavioral tests. Based on this property, we evaluated the effects of besipirdine and its N-despropyl metabolite N-despropyl-besipirdine (P7480) on...
7.
Smith C, Bores G, Petko W, Li M, Selk D, RUSH D, et al.
J Pharmacol Exp Ther
. 1997 Feb;
280(2):710-20.
PMID: 9023283
1-[(3-Fluoro-4-pyridinyl)amino]-3-methyl-1(H)-indol-5-yl methyl carbamate (P10358) is a potent, reversible acetylcholinesterase inhibitor that produces central cholinergic stimulation after oral and parental administration in rats and mice. P10358 is a 2.5 times more...
8.
Zhou L, Vargas H
Eur J Pharmacol
. 1996 Jun;
305(1-3):173-6.
PMID: 8813549
In rats, the pressor response to intravenous (i.v.) phenylephrine is mediated by vascular alpha 1A- and alpha 1B-adrenoceptors, but the role of alpha 1D-adrenoceptors is uncertain. These studies evaluated the...
9.
Bores G, Huger F, Petko W, Mutlib A, Camacho F, RUSH D, et al.
J Pharmacol Exp Ther
. 1996 May;
277(2):728-38.
PMID: 8627552
Acetylcholinesterase (AChE) inhibitors from several chemical classes have been tested for the symptomatic treatment of Alzheimer's disease; however, the therapeutic success of these compounds has been limited. Recently, another AChE...
10.
Camacho F, Smith C, Vargas H, Winslow J
Psychopharmacology (Berl)
. 1996 Apr;
124(4):347-54.
PMID: 8739550
The cholinergic hypothesis of Alzheimer's disease (AD) has strongly influenced research on learning and memory over the last decade. However, there has been limited success treating AD dementia with cholinomimetics....